The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | The rapidly evolving role of transplantation and CAR-T in autoimmune disease
In this video, Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy, comments on the growing interest and rapid evolution in the fields of stem cell transplantation (SCT) and CAR T-cell therapy for autoimmune diseases. Dr Greco highlights that autologous SCT is now established for two indications – multiple sclerosis and systemic sclerosis – offering an opportunity for long-term disease remission and potentially a cure. She also notes that cellular therapy products are showing promising results in treating autoimmune diseases, but more studies are needed in this area. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Regarding the autoimmune disease field, we are really now facing a growing interest and the field is rapidly evolving. For transplantation, we have two main indications that are nowadays standard indications for autologous stem cell transplantation, that are multiple sclerosis and systemic sclerosis. These two indications have really long-term follow-up data stating disease remission...
Regarding the autoimmune disease field, we are really now facing a growing interest and the field is rapidly evolving. For transplantation, we have two main indications that are nowadays standard indications for autologous stem cell transplantation, that are multiple sclerosis and systemic sclerosis. These two indications have really long-term follow-up data stating disease remission. So it is really a concrete and good opportunity for the patient to be cured of their chronic illness. On the other side, we are now entering also in the field of CAR T-cells and also different products of CAR-T, like CAR Tregs or CAR NK cells and so on, trying also to have a role in the autoimmune disease cure. And the results coming from CAR T-cells, although these are at least case reports at the moment, really exciting and promising and I think this can be another opportunity for our patients in the future and what we need now to do is also to do more studies on that as a community to gain more data and for the future to try to look more at what we can do as a tailored, personalized cure for each patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
